To what extent do randomised control trials looking at erenumab follow the International Headache Society’s recommendations; A structured literature review
Item
- Title
- To what extent do randomised control trials looking at erenumab follow the International Headache Society’s recommendations; A structured literature review
- Author(s)
- Kristiansen-Stuart, A
- Abstract
- Background: Erenumab is CGRP inhibitor developed as a prophylactic treatment for migraines. Systematic reviews and meta-analysis has been carried out for previous published literature. The adherence of the studies to the International Headache Society’s guidelines has not yet been examined. Objective: The aim of this study is to critically evaluate the research regarding erenumab on episodic and chronic migraines and how well they adhere to International Headache Society guidelines. Furthermore, to discuss areas of development for future editions of the guidelines as well as areas for further research. Design: Structured literature review. Methods: A systematic search strategy has been conducted which used search terms relevant to the topic in Cochrane Library, Pubmed and Science Direct databases to identify relevant research published between 2016 and 2019. 292 studies found and subjected to filtering using the inclusion and exclusion criteria. The nine suitable studies were summarised in table format and then rated using Downs and Black and a rating scaled based on the International Headache Society guidelines to determine adherence to the guidelines and methodological quality. Results: A good level of adherence to the guidelines was found, with a mean score of eight out of eleven. Good to high levels of methodological quality identified through Downs and Black. Discussion: The potential for funding bias was identified across all studies as well as lack adherence to stratification recommendations and representative patient selection. Recommendations such as the use of headache diary and outcome points were well adhered to by the majority of studies. Scope for further clarification of the quality of the guidelines themselves as well as further research funded by a third party was found. Conclusion: Overall, the results demonstrated a good level of adherence to the guidelines as well as good short term efficacy and tolerability of erenumab. This review highlighted areas of low adherence and scope for further development in future editions of the guidelines.
- presented at
- European School of Osteopathy
- Date Accepted
- 2020
- Date Submitted
- 28.10.2020 18:08:19
- Type
- osteo_thesis
- Language
- English
- Submitted by:
- 62
- Pub-Identifier
- 16670
- Inst-Identifier
- 1229
- Keywords
- Chronic migraine, Episodic migraine, Erenumab, International Headache Society
- Recommended
- 0
- Item sets
- Thesis
Kristiansen-Stuart, A, “To what extent do randomised control trials looking at erenumab follow the International Headache Society’s recommendations; A structured literature review”, Osteopathic Research Web, accessed May 5, 2025, https://www.osteopathicresearch.org/s/orw/item/185